Showing results (21-30 of 317) with videos related to
Sort By:
Pageof 32
Pharmacology & Therapeutics|January 1, 1992
The clinical pharmacology of angiotensin converting enzyme inhibitors in chronic heart failureA D StruthersJournal of Human Hypertension|June 1, 1995
Mineralocorticoid receptor blockade in chronic heart failureA D StruthersEuropean Journal of Clinical Pharmacology|January 1, 1988
Frusemide pretreatment blunts the inhibition of renal tubular sodium reabsorption by ANF in manJ McMurray, A D StruthersClinical Science (London, England : 1979)|April 1, 1988
Effects of angiotensin II and atrial natriuretic peptide alone and in combination on urinary water and electrolyte excretion in manJ McMurray, A D StruthersQJM : Monthly Journal of the Association of Physicians|August 10, 2005
B-type natriuretic peptide: a simple new test to identify coronary artery disease?A D Struthers, J DaviesJournal of Human Hypertension|February 1, 1989
Sympathoadrenal responses during bradycardia-hypotension associated with combined infusion of atrial natriuretic factor and prostaglandin E2J McMurray, A D StruthersBritish Journal of Hospital Medicine|July 1, 1988
Significance of atrial natriuretic factor in chronic heart failureJ McMurray, A D StruthersEuropean Heart Journal|November 20, 1998
Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors?J J McMurrayEuropean Heart Journal|February 3, 1998
Can drug effects on mortality in heart failure be predicted by any surrogate measure?K M Yee, A D StruthersCirculation|February 15, 2000
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failureC A Farquharson, A D StruthersPageof 32